Does reduction in cocaine use represent psychosocial benefit? Ivan D. Montoya, M.D., M.P.H. Deputy Director, NIDA-DPMC.

Slides:



Advertisements
Similar presentations
Standardized Scales.
Advertisements

Survival Analysis In many medical studies, the primary endpoint is time until an event occurs (e.g. death, remission) Data are typically subject to censoring.
Aftercare Attendance Partially Moderated by History of Physical Abuse and Gender Louise F. Haynes 1 ; Amy E. Herrin 1 ; Rickey E. Carter 1 ; Sudie E. Back.
LSU-HSC School of Public Health Biostatistics 1 Statistical Core Didactic Introduction to Biostatistics Donald E. Mercante, PhD.
Background: The low retention rates among African Americans in substance abuse treatment (Milligan et al., 2004) combined with the limited number of treatments.
Objective of the DAP A) Specify an analysis plan that can be applied to a wide variety of clinical HIV resistance studies. B) Include both Intervention.
Substance Use: Substance use comparisons included lifetime and past 30 day use (Figure 3) and lifetime use. For past 30 day use, more men reported heroin.
Journal Club Alcohol, Other Drugs, and Health: Current Evidence November–December 2014.
Journal Club Alcohol, Other Drugs, and Health: Current Evidence March–April 2014.
Journal Club Alcohol, Other Drugs, and Health: Current Evidence March–April 2009.
1 Research Methods in Clinical Psychology Carolyn R. Fallahi, Ph. D.
Journal Club Alcohol, Other Drugs, and Health: Current Evidence September–October 2009.
Lecture 19: Tues., Nov. 11th R-squared (8.6.1) Review
Lecture 24: Thurs. Dec. 4 Extra sum of squares F-tests (10.3) R-squared statistic (10.4.1) Residual plots (11.2) Influential observations (11.3,
Journal Club Alcohol, Other Drugs, and Health: Current Evidence January–February 2011.
Copyright Alcohol Medical Scholars Program1 The Therapeutic Community As Treatment in Substance Use Disorders Laura Pieri, MD Temple University School.
Ch. 14: The Multiple Regression Model building
Journal Club Alcohol, Other Drugs, and Health: Current Evidence January–February 2010.
Chapter 9 - Lecture 2 Computing the analysis of variance for simple experiments (single factor, unrelated groups experiments).
Journal Club Alcohol, Other Drugs, and Health: Current Evidence November–December 2008.
Journal Club Alcohol, Other Drugs, and Health: Current Evidence November–December 2009.
Sample Size Determination
Studying treatment of suicidal ideation & attempts: Designs, Statistical Analysis, and Methodological Considerations Jill M. Harkavy-Friedman, Ph.D.
Marshall University School of Medicine Department of Biochemistry and Microbiology BMS 617 Lecture 12: Multiple and Logistic Regression Marshall University.
Repeated measures: Approaches to Analysis Peter T. Donnan Professor of Epidemiology and Biostatistics.
Copyright © 2013, 2009, and 2007, Pearson Education, Inc. Chapter 12 Analyzing the Association Between Quantitative Variables: Regression Analysis Section.
Treatment for Adolescents With Depression Study (TADS)
METHODS Sample n=245 Women, 24% White, 72% Average age, 36.5 Never married, 51% Referral Sources (%) 12-Month DSM-IV Substance Dependence Prior to Entering.
Lecture 6: Reliability and validity of scales (cont) 1. In relation to scales, define the following terms: - Content validity - Criterion validity (concurrent.
INTRO TO EXPERIMENTAL RESEARCH, continued Lawrence R. Gordon Psychology Research Methods I.
Growth Mixture Modeling of Longitudinal Data David Huang, Dr.P.H., M.P.H. UCLA, Integrated Substance Abuse Program.
Substance Abuse, Medication Adherence, and Criminality among Mentally Ill Parolees David Farabee & Sylvia Sanchez UCLA Integrated Substance Abuse Programs.
CCTN September 6 th, Recent Scientific Publications from the Clinical Trials Network David Liu, M.D. (CTN-0029) Harold Perl, Ph.D. (CTN-0015) Paul.
Biostatistics Case Studies 2008 Peter D. Christenson Biostatistician Session 5: Choices for Longitudinal Data Analysis.
ACAMPROSATE Efficacy Results from Three Pivotal Efficacy Trials Karl F. Mann, M.D. Professor and Chairman Director, Department of Addictive Behavior and.
Raymond F. Anton, MD for The COMBINE Study Research Group
HSRP 734: Advanced Statistical Methods July 17, 2008.
Abstinence Incentives for Methadone Maintained Stimulant Users: Outcomes for Those Testing Stimulant Positive vs Negative at Study Intake Maxine L. Stitzer.
Methamphetamine: User Characteristics and Treatment Response Alice Huber, Ph.D. Steven Shoptaw, Ph.D. Richard A. Rawson, Ph.D. Paul Brethen, M.A. Walter.
Lecture 9: Analysis of intervention studies Randomized trial - categorical outcome Measures of risk: –incidence rate of an adverse event (death, etc) It.
Three Statistical Issues (1) Observational Study (2) Multiple Comparisons (3) Censoring Definitions.
Abstinence Incentive Effects in Psychosocial Counseling Patients Testing Stimulant Positive vs Negative at Treatment Entry Maxine L. Stitzer Johns Hopkins.
Table 1. Prediction model for maximum daily dose of buprenorphine-naloxone in a 12-week treatment condition Baseline Predictors Maximum Daily Dose Standardized.
1 Lecture 6: Descriptive follow-up studies Natural history of disease and prognosis Survival analysis: Kaplan-Meier survival curves Cox proportional hazards.
©2010 John Wiley and Sons Chapter 2 Research Methods in Human-Computer Interaction Chapter 2- Experimental Research.
Relational Discord at Conclusion of Treatment Predicts Future Substance Use for Partnered Patients Wayne H. Denton, MD, PhD; Paul A. Nakonezny, PhD; Bryon.
Applied Quantitative Analysis and Practices LECTURE#25 By Dr. Osman Sadiq Paracha.
F UNCTIONAL L IMITATIONS IN C ANCER S URVIVORS A MONG E LDERLY M EDICARE B ENEFICIARIES Prachi P. Chavan, MD, MPH Epidemiology PhD Student Xinhua Yu MD.
Copyright © 2013, 2009, and 2007, Pearson Education, Inc. Chapter 10 Comparing Two Groups Section 10.1 Categorical Response: Comparing Two Proportions.
Combined Pharmacological and Behavioral Therapy and HIV Risk Reduction Jennifer Schroeder, David Epstein, Katherine Belendiuk, Jessica Willner-Reid, John.
1 Efficacy of Acamprosate: Clinical Issues Celia Jaffe Winchell, M.D. Medical Team Leader Addiction Drug Products.
Ten Years of Pharmacotherapy Trials in the CTN: An Overview.
Factors associated with concurrent Heroin use among patients on Methadone maintenance treatment in Vietnam from 2008 to 2013 Hoang Nam Thai MD, MPH – CDC/DGHT.
Rate of Visual Field Progression in Eyes With Optic Disc Hemorrhages in the Ocular Hypertension Treatment Study De Moraes CG, Demirel S, Gardiner SK, et.
J. Aaron Johnson, PhD 1 and J. Paul Seale, MD 2 1 Institute of Public and Preventive Health and Department of Psychology, Georgia Regents University, Augusta,
Augmentation of Exposure-Based Cognitive Behavioral Therapy with D-cycloserine in Patients with Panic Disorder Sean Donovan, Meenakshi Shelat, Corrinne.
Tetrabenazine (Xenazine ® ) Prestwick Pharmaceuticals NDA Peripheral and Central Nervous System Drugs Advisory Committee Meeting Beltsville, Maryland.
1 Research Methods in Child Psychopathology Carolyn R. Fallahi, Ph. D.
Randomized Controlled CTN Trial of OROS-MPH + CBT in Adolescents with ADHD and Substance Use Disorders Paula Riggs, M.D., Theresa Winhusen, PhD., Jeff.
Medication Adherence and Substance Abuse Predict 18-Month Recidivism among Mental Health Jail Diversion Program Clients Elizabeth N. Burris 1, Evan M.
Chapter 11: Test for Comparing Group Means: Part I.
Methadone maintenance in Michigan: Five years of data using a contingency management approach Gary Rhodes, M.A., L.L.P. Golfo Tzilos, M.A. Mark Greenwald,
Education 793 Class Notes ANCOVA Presentation 11.
Date of download: 9/20/2016 Copyright © 2016 American Medical Association. All rights reserved. From: Effects of a Palliative Care Intervention on Clinical.
One-Year Post-Treatment COMBINE Study Drinking Outcomes Dennis M. Donovan, Ph.D. for the COMBINE Study Research Group Research Society on Alcoholism Baltimore,
Sofija Zagarins1, PhD, Garry Welch1, PhD, Jane Garb2, MS
Applied Biostatistics: Lecture 2
L.S. Remy1, G. Woody2, K. Lynch2, K. M. Kampman2
Clinical outcome after SVR: Veterans Affairs
Analyzing Intervention Studies
Presentation transcript:

Does reduction in cocaine use represent psychosocial benefit? Ivan D. Montoya, M.D., M.P.H. Deputy Director, NIDA-DPMC

Specific Questions 1.Are quantitative urine cocaine results associated with psychosocial measures independent of treatment? 2.Are changes in quantitative urine cocaine results associated with psychosocial changes during treatment? 3.Is a percent reduction of quantitative cocaine urine associated with psychosocial changes?

What we have… Data from 7 Phase II, double-blind RCTs of pharmacotherapies for cocaine dependence Conducted by NIDA Quantitative urine toxicology analysis thrice weekly Study medication (n) – Baclofen (n=160) – Ondansetron (n=63) – Selegiline (n=300) – Carbergoline (140) – Modafinil (210) – Reserpine (140) – Tiagabine (140) Manual-based weekly individual cognitive behavioral therapy 8-week treatment (n=523) 12-week treatment (n=630) N=1,153

Outcome variables – Addiction Severity Index (ASI) – Clinical Global Impressions (CGI) Observed Self-rated Severity Improvement – Brief Substance Craving Scale (BSCS)

Q1. Are quantitative urine cocaine results associated with psychosocial scores? Lower cocaine use associated with better psychosocial function Independent of treatment time Linear regression

ASI

Clinical Global Impression (CGI) Observer & Self-Rated * *Adj R-Square: 0.13 P = 0.017

Brief Substance Craving Scale Adjusted R-Square: 0.14 P=0.016

Q2. Are changes in quantitative urine cocaine results associated with psychosocial changes during treatment? Cocaine Use Psychosocial Treatment Weeks Psychosocial Treatment Weeks Psychosocial Treatment Weeks

Data Analysis For each participant during treatment: – Slope of log-10 BE vs. – Slope of ASI CGI scores Self-reported cocaine use Treatment Retention Regression coefficient and p value

ASI *

Clinical Global Improvement (CGI) Observer & Self-Rated

Brief Substance Craving Scale

Quantitative Urine BE and Self-Reported Cocaine Use

Self-report was coded: USE: if the use on at least one of three days prior to urine test NON-USE: no use if the participants reported no use for all three prior days The simple Kappa coefficient can’t be used because the data are longitudinal and individuals provided multiple self report/BE pairs of observations. The longitudinal structure required special handling of confidence interval construction using “bootstrap” technique. Values between 0.40 and 0.75 represent good agreement.

Retention was shorter for those who decreased use most rapidly (first quartile) and those who increased use (fourth quartile) Quantitative Urine Result and Retention in Treatment

Q3. Is a percent in reduction of quantitative urine cocaine results associated with psychosocial improvements? Treatment groups – Success: reduction of 50% or more in urine BE between baseline and end of treatment – Failure: Reduction of less than 50% Separate analysis for 8- and 12-week studies because of significant differences at baseline and EOT End of treatment (EOT)* Weeks 6-8 for 8-week studies Weeks 9-12, for 12-week studies Comparison between treatment failure and success groups – Difference in mean scores between baseline and EOT for each outcome variable Subjects with missing data were excluded from the analysis Stepdown Bonferroni correction t-tests

Difference in Mean ASI Scores between Treatment Failure and Success (8-week study, n:~130) ______________ ASI Drug Score ______________ ASI Alcohol Score Mean ASI Score

Difference in Mean ASI Scores between Treatment Failure and Success (8-week study, n:~130) ______________ ASI Legal Score ______________ ASI Family Score Mean ASI Score ______________ ASI Medical Score ______________ ASI Psychiatric Score

Difference in Mean Brief Substance Craving Score between Treatment Failure and Success 8-week (study, n=399) Mean BSC Score * * p<.01

Difference in Mean Clinical Global Impression Severity Scores between Treatment Failure and Success 8-week (study, n=394) _________________ CGI Self-Rated Score _________________ CGI Observed Score Mean CGI Score * * * p<.01

Difference in Mean ASI Scores between Treatment Failure and Success (12-week study, n=314) Mean ASI Score *

Difference in Mean BSCS, CGI-O and CGI-S between Treatment Failure and Success (12-week study, n=405) Mean Score * p<.01 * **

Summary 1.Are quantitative urine cocaine results associated with psychosocial measures independent of treatment? ASI: No CGI Severity: Possibly

Summary 1.Are quantitative urine cocaine results associated with psychosocial measures? 2.Are changes in quantitative urine cocaine results associated with psychosocial changes during treatment? – ASI: No – CGI Severity: Possibly – Self-reported cocaine use: yes – Retention: yes

Summary 3. Is a percent reduction of quantitative cocaine urine (success vs. failure) associated with psychosocial changes? – 8-week studies: No significant change in all ASI domains Treatment success: significant reduction of craving and improvement of CGI Severity Observed and Self-rated – 12-week studies: No significant changes in most ASI domains Treatment success: significant reduction of craving and improvement of CGI Severity Observed and Self-rated

Conclusions ASI may not be sensitive to tx change CGI-O and CGI-S: appear sensitive measures Self-reported drug use is somewhat reliable Cocaine use affects retention in treatment 50% reduction in urine quantitative (“treatment success”) is associated with improvement in CGI-O, CGI-S and Craving (in 8- and 12-week tx regimens)

NIDA Funding Opportunities

Clinical Global Impressions (CGI) Considering your total clinical experience with this particular population, how mentally ill is the patient at this time? – 1: Normal – 7: The worst Compared to the patient’s condition at admission, it is: – 1: Very much improved – 7: Very much worse

Quantitative Urine Result and Retention in Treatment Estimated the rate of change in use by regressing logarithm-base-10 urine BE on days elapsed since randomization during the active intervention period. Subjects were then classified into four groups based on the quartiles of these estimates of rate of change in use. Retention was defined as days elapsed on study and those who reached study end were classified as right censored. Survival curves for retention were estimated (Kaplan-Meier) separately for each quartile of rate of change in use.